Canada Markets close in 3 hrs 41 mins

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6550+0.0042 (+0.65%)
As of 12:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.6508
Open0.6590
Bid0.6172 x 1300
Ask0.6551 x 1100
Day's Range0.6200 - 0.6600
52 Week Range0.5610 - 2.3500
Volume19,444
Avg. Volume25,217
Market Cap11.106M
Beta (5Y Monthly)-0.08
PE Ratio (TTM)N/A
EPS (TTM)-0.3180
Earnings DateNov 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th

    NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B.

  • GlobeNewswire

    Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update

    NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the third quarter ended September 30, 2021. Recent Highlights Hosted a virtual science review to discuss the scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction. Replay available at www.protagenic.com.Hosted a key opinion l

  • GlobeNewswire

    Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET

    Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a Scientific review of its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction. The review will take place o